Drug intelligence / Profile preview

PF-07293893

Development stage: Phase 1
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

PF-07293893 is an investigational small molecule drug developed by Pfizer, currently in Phase 1 clinical trials for the treatment of heart failure, including congestive heart failure. It acts as an activator of adenosine monophosphate activated protein kinase gamma 3 (AMPKγ3), a key regulator of cellular energy homeostasis. The drug is administered orally and is being studied for its effects on muscle biomarkers and exercise capacity in patients with heart disease who have reduced ability to exercise. As of now, it has not received FDA approval or any special regulatory designation.

Targets

PRKAG3 (AMPK gamma-3)

Beyond the preview

Go deeper on PF-07293893.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-07293893.

Explore the full profile